相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework
Nicolle M. Gatto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2022)
How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers?
Marc L. Berger et al.
VALUE IN HEALTH (2022)
The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness
Noelle M. Cocoros et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies First Results From the RCT DUPLICATE Initiative
Jessica M. Franklin et al.
CIRCULATION (2021)
STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies
Shirley Wang et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting
Nicole L. Pratt et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials
Jessica M. Franklin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility
Donna R. Rivera et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Issues in the registration of database studies
Deborah A. Zarin et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2020)
被撤回的出版物: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (Publication with Expression of Concern. See vol. 382, pg. 2464, 2020) (Retracted article. See vol. 382, pg. 2582, 2020)
Mandeep R. Mehra et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative
Lucinda S. Orsini et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Retraction of COVID-19 Pharmacoepidemiology Research Could Have Been Avoided by Effective Use of Reporting Guidelines
Eric Benchimol et al.
CLINICAL EPIDEMIOLOGY (2020)
The ENCePP Code of Conduct: A best practise for scientific independence and transparency in noninterventional postauthorisation studies
Rosa Gini et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2019)
Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies Avoiding Immortal Time Bias
Samy Suissa
CIRCULATION (2018)
Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)
Xavier Kurz et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2018)
Real world evidence: experience and lessons from China (vol 360, j5262, 2018)
Xin Sun et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Real world evidence: experience and lessons from China (vol 360, j5262, 2018)
Xin Sun et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study
Anton Pottegard et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0
Shirley V. Wang et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making
Marc L. Berger et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available
Miguel A. Hernan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)
The FDA's Sentinel Initiative-A Comprehensive Approach to Medical Product Surveillance
R. Ball et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness
Nancy A. Dreyer et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2016)
A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report
Marc L. Berger et al.
VALUE IN HEALTH (2014)
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies
Erik von Elm et al.
PLOS MEDICINE (2007)
Immortal time bias in observational studies of drug effects
Samy Suissa
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
分享论文
